Vancomycin resistant enterococci

Burns

Volumn 24, Issue 5, 1998, Pages 389-391

  Holder, I A ^a   Neely, A N ^a  

^a Shriner's Burns Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AZTREONAM; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; IMIPENEM; METICILLIN; SULFAMETHOXAZOLE; TEICOPLANIN; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BURN; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; EPIDEMIOLOGICAL DATA; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; OSTEOMYELITIS; PHENOTYPE; RISK FACTOR; SHORT SURVEY;

EID: 0032144114     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-4179(98)00023-0     Document Type: Article

References (27)

1. [1] Holder IA, Neely AN. Fear of MRSA - potential for future disaster. Burns 1997; in press.
2. [2] CDC recommendations for preventing the spread of vancomycin resistance Resistance of the hospital control practice advisory committee (HICPAC). Morb Mortal Wkly Rep 1995;44:1-13.
3. [3] Recommendations for preventing the spread of vancomycin resistance from the hospital control practices advisory committee (HICPAC). Drug Benefit Trends 1996;8:2227.
4. [4] Zellweger G, Simmen JP, Meyer VE, Kayser FH. Infection in the upper body: hand and burn-wound microbiology and considerations for antimicrobial therapy. J Burn Care Rehabil 1992;13:298-304.
5. [5] Vindenes H, Bjerknes R. Microbial colonization of large wounds. Burns 1995;21:575-579.
6. [6] Donati L, Scamazzo F, Gervasoni M et al. Infection and antibiotic therapy in 4000 burned patients treated in Milan, Italy, between 1976 and 1988. Burns 1993;19:345-348.
7. [7] Law EJ, Belcher K, Still JM. Enterococcal infections as a cause of mortality and morbidity in patients with burns. J Burn Care Rehabil 1994;15:236-239.
8. [8] Smith DJ Jr, Thompson PD. Changing flora in burn and trauma units: historical perspective - experience in the United States. J Burn Care Rehabil 1992;13:276-280.
9. [9] Spera RV Jr, Farber BF. Multiply resistant Enterococcus faecium: the nosocomial pathogen of the 1990s. JAMA 1992;268:2563-2564.
10. [10] Heath CH, Blackmore TK, Gordon DL. Emerging resistance in enterococcus sp. Med J Australia 1996;164:116-120.
11. [11] Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990;3:45-58.
12. [12] Perlada DE, Smulian AG, Cushian MT. Molecular epidemiology and antibiotic susceptibility of enterococci in Cincinnati, Ohio; a prospective city-wide study. J Clin Microbiol 1997;35:2342-2347.
13. [13] Leclercq R, Courvlin P. Resistance of glycopeptides in enterococci. Clin Infect Dis 1997;24:545-556.
14. [14] Uttley AH, George RC, Naidoo J et al. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989;103:173-181.
15. [15] Rice LB, Shlaes DM. Vancomycin resistance in the enterococcus: relevance in pediatrics. Pediatric Cl N Am 1995;42:601-618.
16. [16] Perichon B, Reynolds PE, Courvalin P. Van D-type glycopeptide resistant Enterococcus faecium BM 4339. Antimicrob Agents Chemother 1997;41:2016-2021.
17. [17] Evers S, Casadevall B, Charles M et al. Evolution of structure and substrate specificity in D-alanine-D-alanine ligases and related enzymes. J Mol Evol 1996;42:706-712.
18. [18] Korten V, Murray BE. The nosocomial transmission of enterococci. Current Opinion Infect Dis 1993;6:498-505.
19. [19] Rubin LG, Tucci V, Cercendao E, Eliopoulos G, Isenberg HD. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol 1992;13:700-705.
20. [20] Karanfil LV, Murphy M, Josephson A et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992;3:195-200.
21. [21] Handwerger S, Raucher B, Altarac D. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993;16:750-755.
22. [22] Frieden TR, Munsiff SS, Low DE et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet 1993;342:76-79.
23. [23] Montecalvo MA, Horowitz H, Gedris C et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994;38:1363-1367.
24. [24] Boyce JM, Opal SM, Chow JW et al. Outbreak of multi-drug resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994;32:1148-1153.
25. [25] Livornese LL Jr, Dias S, Samel C et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992;117:112-116.
26. [26] White AC Jr, Atmar RL, Wilson J et al. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997;25:230-239.
27. [27] Quale J, Landman D, Guillermo S et al. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23:1020-1025.